Joint NORDICPedMed / PIF Nordic Conference on Pediatric Medicines 13th June, Helsinki, Finland



Nordic collaboration can increase pediatric medicines research opportunities by providing;

- Larger child population (5.2 million < 18 yrs. old)
- Strong position within Europe (Enpr-EMA) and in new European Research Infrastructure initiatives
- High-quality research environment for pediatric medicines in similar health-care systems with high-tech solutions, and unique system of national registers, patient and biological sample data, and statistics
- Scientific and administrative competence at a Nordic level
- Ethical aspects for pediatric clinical trials
- ⇒ Benefits for children in Nordic countries & opportunities for early access to new promising medicines

Topics

- Regulatory up-date by EMA / PDCO (Pediatric Committee)
- Network up-date by Nordic National Pediatric Research Networks and NordicPedMed
- Industry perspectives for pediatric medicines development and Nordic strengths
- New European level initiatives & infrastructures for Pediatric Clinical Trials
- Nordic area & collaboration as its best by all stakeholders Discussion

Time: 13th June, 10:15 a.m. - 17:00 p.m.

Venue: Leonardo da Vinci Auditorium, Itämerenkatu 11-13, Gräsviken / Ruoholahti, Helsinki, Finland

Registration and Information link

Organized by:

























Det nationella nätverket för forskning av barnläkemede
Kansallinen lastenlääkkeiden tutkimusverkosto





Program 13.6.2017:

REGISTRATION open: 10.15 a.m.-10:45 a.m.

10:50 Welcome – Mia Bengtström, PIF, Finland

- 1. 11:00: EFPIA Up-date Pediatric Working Group TBC
- 2. 11:20: EMA Regulatory up-date PDCO Ann Marie Kaukonen, Finland
- 3. 11:40: EMA Regulatory up-date PDCO Siri Wang, Norway
- 4. 12:00: FinPedMed & IcePedMed Pirkko Lepola, Finland
- 5. 12:10: NorPedMed –Thomas Halvorsen, Norway
- 6. 12:20: SwedPedMed –Anders Rane, Sweden
- 7. 12:30: DanPedMed –Helle Holst, Denmark
- 8. 12:40: NordicPedMed –Kalle Hoppu, Finland

13:00- 13:55 Lunch

- 9. 13:55: Ethical aspects in pediatric Clinical Trials Nordic advantages Pirkko Lepola, Finland
- 10. 14:15: International collaboration: the global picture –Mark Turner, UK
- 11. 14:45: Pharma Industry expectations for Pediatric research Heidrun Hildebrand, Bayer AG, Germany

15:15- 15:45: Coffee

- 12. 15:45: Paediatric Early Phase Trials Unit, TAYS, Sauli Palmu, Finland
- 13. 16:05: Discussion all stakeholders; Q & A and The way forward?
- 16:50- 17:00 Closing remarks, End of the day Mia Bengtström